Akira Mita

Title: Akira Mita: Innovator in Anticancer Drug Administration

Introduction

Akira Mita is a notable inventor based in Chiyoda-ku, Japan. He has made significant contributions to the field of oncology through his innovative methods of drug administration. With a total of 3 patents, Mita's work focuses on improving cancer treatment efficacy and patient outcomes.

Latest Patents

Mita's latest patents include a method for administering an anticancer drug that combines α,α,α-trifluorothymidine and a thymidine phosphorylase inhibitor. This invention relates to a method for treating cancer by orally administering a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a specific molar ratio. The recommended dosage ranges from 20 to 80 mg/m/day in divided portions for patients in need of treatment. Another significant patent involves a cytidine derivative-containing antitumor agent designed for continuous intravenous administration. This method allows for continuous therapy without causing peripheral neurotoxicity, thereby enhancing therapeutic effects and prolonging patient survival.

Career Highlights

Akira Mita is currently associated with Taiho Pharmaceutical Company Limited, where he continues to develop innovative solutions for cancer treatment. His work has been instrumental in advancing the field of oncology and improving the quality of life for patients undergoing treatment.

Collaborations

Mita collaborates with talented professionals, including Tomohiro Emura and Hiromi Kazuno, who contribute to his research and development efforts. Their combined expertise fosters a collaborative environment that drives innovation in cancer therapies.

Conclusion

Akira Mita's contributions to the field of oncology through his innovative patents demonstrate his commitment to improving cancer treatment. His work not only enhances therapeutic efficacy but also aims to improve patient quality of life.